Mizuho Maintains Buy on Credo Technology Group, Raises Price Target to $21

Mizuho analyst Vijay Rakesh maintains Credo Technology Group (NASDAQ:CRDO) with a Buy and raises the price target from $19 to $21.

byBenzinga Newsdesk

March 10, 2022

1 minute read

Mizuho analyst Vijay Rakesh maintains Credo Technology Group (NASDAQ:CRDO) with a Buy and raises the price target from $19 to $21.

Dare Bioscience Reports Initiation Of Phase 1/2 Study Of DARE-VVA1 For Treatment Of Vulvar, Vaginal Atrophy

By Benzinga Newsdesk

Today, 4:42 AM

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal tamoxifen product being

DARE

Tesla Bet Upped By 160%, Apple Dumped And More: How Canada’s Largest Pension Fund Shuffled Its Q4 Portfolio

By Shanthi Rexaline

Today, 4:42 AM

Even as most U.S. fund managers hoarded tech stocks at bargain prices following their sell-off last year, Canada’s biggest pension fund deemed it fit to sell some prominent tech names.

AAPL

FDA
News

Prelude Therapeutics Announces Presentation Of Data From Multiple Programs At AACR-NCI-EORTC Virtual International Conference

By Benzinga Newsdesk

Today, 4:42 AM

Prelude Therapeutics Inc. (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the presentation of data from multiple pipeline programs, including the dose escalation portions of the Company's

PRLD